X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (2974) 2974
Book Review (1226) 1226
Publication (290) 290
Book Chapter (21) 21
Conference Proceeding (4) 4
Book / eBook (3) 3
Dissertation (1) 1
Magazine Article (1) 1
Newspaper Article (1) 1
Patent (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (2406) 2406
humans (2219) 2219
oncology (1517) 1517
male (930) 930
cancer (916) 916
female (882) 882
refractory solid tumors (725) 725
middle aged (672) 672
chemotherapy (628) 628
aged (602) 602
adult (560) 560
animals (515) 515
antineoplastic agents - therapeutic use (513) 513
care and treatment (513) 513
pharmacology & pharmacy (505) 505
hematology (490) 490
treatment outcome (476) 476
research (372) 372
antineoplastic combined chemotherapy protocols - therapeutic use (370) 370
neoplasms - drug therapy (344) 344
phase-ii trial (328) 328
medicine & public health (307) 307
tumors (304) 304
phase-i (278) 278
clinical trials (266) 266
health aspects (264) 264
aged, 80 and over (259) 259
drug therapy (259) 259
child (254) 254
therapy (252) 252
clinical trials as topic (247) 247
analysis (244) 244
prognosis (239) 239
antineoplastic agents - pharmacology (238) 238
solid tumors (226) 226
adolescent (222) 222
antineoplastic agents - adverse effects (218) 218
patients (215) 215
antineoplastic agents (213) 213
refractory prostate-cancer (209) 209
phase-i trial (206) 206
immunotherapy (205) 205
phase-ii (202) 202
antimitotic agents (200) 200
metastasis (200) 200
sorafenib (196) 196
refractory (195) 195
refractory multiple-myeloma (192) 192
apoptosis (191) 191
pharmacokinetics (190) 190
antitumor-activity (189) 189
hematology, oncology and palliative medicine (186) 186
pediatrics (184) 184
drug resistance, neoplasm (178) 178
disease-free survival (177) 177
article (175) 175
survival (175) 175
niacinamide - analogs & derivatives (172) 172
endothelial growth-factor (171) 171
medical research (164) 164
multiple myeloma (163) 163
antineoplastic combined chemotherapy protocols - adverse effects (162) 162
toxicity (162) 162
trial (162) 162
antineoplastic agents - administration & dosage (160) 160
refractory materials (160) 160
children (158) 158
review (158) 158
acute myeloid-leukemia (154) 154
bortezomib (153) 153
cell lung-cancer (153) 153
dose-response relationship, drug (153) 153
cell line, tumor (152) 152
retrospective studies (149) 149
transplantation (148) 148
child, preschool (143) 143
pharmacology/toxicology (143) 143
immunology (142) 142
leukemia (142) 142
development and progression (139) 139
cancer therapies (138) 138
mice (138) 138
prostate cancer (138) 138
survival rate (137) 137
young adult (137) 137
drug administration schedule (135) 135
non-hodgkins-lymphoma (135) 135
antibodies, monoclonal - therapeutic use (134) 134
angiogenesis (132) 132
risk factors (131) 131
proteins (125) 125
carcinoma (124) 124
combination (124) 124
lymphoma (124) 124
lymphomas (122) 122
antineoplastic agents - pharmacokinetics (121) 121
dosage and administration (121) 121
abridged index medicus (120) 120
breast-cancer (120) 120
chronic lymphocytic-leukemia (120) 120
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (2952) 2952
French (14) 14
Spanish (10) 10
Korean (7) 7
German (6) 6
Japanese (6) 6
Polish (4) 4
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


British Journal of Cancer, ISSN 0007-0920, 2019, Volume 121, Issue 2, pp. 131 - 138
Anaplastic lymphoma kinase (ALK) gene rearrangements are oncogenic drivers in non-small-cell lung cancer (NSCLC). TSR-011 is a dual ALK and tropomyosin-related... 
ONCOLOGY | LUNG | CRIZOTINIB RESISTANCE | Slopes | Tropomyosin | Lung cancer | Pharmacology | Kinases | Lymphoma | Patients | Refractory materials | Inhibitors | Safety | Solid tumors | Pharmacokinetics | Protein-tyrosine kinase | Tumors
Journal Article
Cancer Chemotherapy and Pharmacology, ISSN 0344-5704, 2019, Volume 83, Issue 6, pp. 1025 - 1035
This study was conducted to define the maximum tolerated dose (MTD), recommended phase two dose (RPTD), and toxicities of gemcitabine + dasatinib (GD) and... 
Dasatinib | Phase I | Gemcitabine | Cetuximab | Pancreatic cancer | Research | Bilirubin | Oncology, Experimental | Cancer | Adenocarcinoma | Thrombocytopenia | Edema | Epidermal growth factor receptors | Anemia | Toxicity | Medical services | Patients | ErbB-2 protein | Refractory materials | Pneumonitis | Biopsy | Vomiting | Biomarkers | Skin | Bioindicators | Solid tumors | Colitis | Tumors | Neutropenia
Journal Article
Journal Article
Journal Article
The Journal of Clinical Pharmacology, ISSN 0091-2700, 02/2018, Volume 58, Issue 2, pp. 180 - 192
Journal Article
European Journal of Cancer, ISSN 0959-8049, 2012, Volume 48, Issue 18, pp. 3319 - 3327
Abstract Background SF1126 is a peptidic pro-drug inhibitor of pan-PI3K/mTORC. A first-in-human study evaluated safety, dose limiting toxicities (DLT), maximum... 
Hematology, Oncology and Palliative Medicine | Pharmacodynamics | PI3K/mTORC pathway | SF1126 | Pharmacokinetics | Refractory solid tumours | B-cell malignancies | ACTIVATION | ANGIOGENESIS | PHOSPHATIDYLINOSITOL 3-KINASE | KINASE | GUIDELINES | CANCER | ONCOLOGY | PI3K PATHWAY | CHRONIC LYMPHOCYTIC-LEUKEMIA | INHIBITOR | ASSOCIATION | Humans | Middle Aged | Male | Neoplasm Proteins - antagonists & inhibitors | Antineoplastic Agents - therapeutic use | Antineoplastic Agents - administration & dosage | Protein Kinase Inhibitors - adverse effects | Phosphatidylinositol 3-Kinases - antagonists & inhibitors | Oligopeptides - therapeutic use | Young Adult | Chromones - adverse effects | Aged, 80 and over | Antineoplastic Agents - pharmacokinetics | Chromones - pharmacology | Protein Kinase Inhibitors - pharmacokinetics | Lymphoma, Large B-Cell, Diffuse - drug therapy | Lymphoma, Large B-Cell, Diffuse - enzymology | Neoplasms - drug therapy | Protein Kinase Inhibitors - administration & dosage | Leukemia, Lymphocytic, Chronic, B-Cell - enzymology | Maximum Tolerated Dose | Oligopeptides - administration & dosage | TOR Serine-Threonine Kinases | Leukemia, Lymphocytic, Chronic, B-Cell - drug therapy | Oligopeptides - pharmacology | Proteins - antagonists & inhibitors | Prodrugs - administration & dosage | Multiprotein Complexes | Salvage Therapy | Chromones - administration & dosage | Molecular Targeted Therapy | Oligopeptides - adverse effects | Mechanistic Target of Rapamycin Complex 1 | Dose-Response Relationship, Drug | Antineoplastic Agents - adverse effects | Hypokalemia - chemically induced | Adult | Female | Antineoplastic Agents - pharmacology | Chromones - therapeutic use | Hematologic Diseases - chemically induced | Oligopeptides - pharmacokinetics | Neoplasms - enzymology | Chromones - pharmacokinetics | Prodrugs - adverse effects | Prodrugs - pharmacokinetics | Protein Kinase Inhibitors - therapeutic use | Aged | Prodrugs - therapeutic use | Protein Kinase Inhibitors - pharmacology | Infusions, Intravenous | Prodrugs - pharmacology | Gastrointestinal Diseases - chemically induced | Medicine, Experimental | Medical research | Care and treatment | Emergency medical services | Cancer | Index Medicus | PI3K | mTORC pathway
Journal Article
Cancer Chemotherapy and Pharmacology, ISSN 0344-5704, 10/2013, Volume 72, Issue 4, pp. 861 - 868
Journal Article
Clinical and Translational Oncology, ISSN 1699-048X, 12/2016, Volume 18, Issue 12, pp. 1243 - 1253
Journal Article
Pediatrics International, ISSN 1328-8067, 05/2019, Volume 61, Issue 5, pp. 453 - 458
Although irinotecan hydrochloride (IRI) is a promising chemotherapeutic agent for pediatric solid tumors, its indications had been off-label in the USA, EU and... 
solid tumor | registration | irinotecan | phase 1/2 | children | PROTRACTED IRINOTECAN | NEUROBLASTOMA | II TRIAL | TEMOZOLOMIDE | phase 1 | ONCOLOGY | TEMSIROLIMUS | RECURRENT | PEDIATRICS | SCHEDULE | Antimitotic agents | Pediatrics | Chemotherapy | Product development | Antineoplastic agents | Cancer | Tumors | Irinotecan | Refractory materials | Schedules | Toxicity | Shrinkage | Children | Solid tumors
Journal Article
Investigational New Drugs, ISSN 0167-6997, 2/2013, Volume 31, Issue 1, pp. 77 - 84
Journal Article
Journal Article